English
简体中文
Total: £ 56.28
Published Date: 2026-02-03 | Pages: 138 | Tables: 136 | Medical Care
The global End-stage Renal Disease Therapeutics market was valued at US$ 8244 million in 2025 and is anticipated to reach US$ 12410 million by 2032, at a CAGR of 6.1% from 2026 to 2032.
End-stage Renal Disease Therapeutics refers to a specialized range of medical treatments and medications aimed at managing chronic kidney disease as it progresses to advanced stages, particularly stages 4 and 5. These therapies are designed to slow further decline in kidney function, alleviate symptoms, improve quality of life, and prolong survival. Common treatments include hemodialysis, peritoneal dialysis, and kidney transplantation. In terms of medications, doctors may prescribe antihypertensive drugs, phosphate binders, and erythropoiesis-stimulating agents to manage associated complications, such as hypertension, anemia, and bone disorders in late-stage CKD patients.
The North American market for End-stage Renal Disease Therapeutics is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for End-stage Renal Disease Therapeutics is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for End-stage Renal Disease Therapeutics in Hospital is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of End-stage Renal Disease Therapeutics include Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, Nipro, Weigao, Toray, Medtronic, JMS, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global End-stage Renal Disease Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding End-stage Renal Disease Therapeutics. The End-stage Renal Disease Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global End-stage Renal Disease Therapeutics market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist End-stage Renal Disease Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Fresenius
Nikkiso
B.Braun
Baxter
Asahi Kasei
Nipro
Weigao
Toray
Medtronic
JMS
SB-KAWASUMI
Medica Group
Chongqing Shanwaishan
Amgen
Deltanoid
AbbVie
Sanofi
Ardelyx
AstraZeneca
Kyowa Hakko Kirin
Segment by Type
Drugs
Device
Other
Segment by Application
Hospital
Dialysis Center
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for End-stage Renal Disease Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global End-stage Renal Disease Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Drugs
1.2.3 Device
1.2.4 Other
1.3 Market by Application
1.3.1 Global End-stage Renal Disease Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Dialysis Center
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global End-stage Renal Disease Therapeutics Market Perspective (2021–2032)
2.2 Global End-stage Renal Disease Therapeutics Growth Trends by Region
2.2.1 Global End-stage Renal Disease Therapeutics Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 End-stage Renal Disease Therapeutics Historic Market Size by Region (2021–2026)
2.2.3 End-stage Renal Disease Therapeutics Forecasted Market Size by Region (2027–2032)
2.3 End-stage Renal Disease Therapeutics Market Dynamics
2.3.1 End-stage Renal Disease Therapeutics Industry Trends
2.3.2 End-stage Renal Disease Therapeutics Market Drivers
2.3.3 End-stage Renal Disease Therapeutics Market Challenges
2.3.4 End-stage Renal Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top End-stage Renal Disease Therapeutics Players by Revenue
3.1.1 Global Top End-stage Renal Disease Therapeutics Players by Revenue (2021–2026)
3.1.2 Global End-stage Renal Disease Therapeutics Revenue Market Share by Players (2021–2026)
3.2 Global Top End-stage Renal Disease Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by End-stage Renal Disease Therapeutics Revenue
3.4 Global End-stage Renal Disease Therapeutics Market Concentration Ratio
3.4.1 Global End-stage Renal Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by End-stage Renal Disease Therapeutics Revenue in 2025
3.5 Global Key Players of End-stage Renal Disease Therapeutics Head Offices and Areas Served
3.6 Global Key Players of End-stage Renal Disease Therapeutics, Products and Applications
3.7 Global Key Players of End-stage Renal Disease Therapeutics, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 End-stage Renal Disease Therapeutics Breakdown Data by Type
4.1 Global End-stage Renal Disease Therapeutics Historic Market Size by Type (2021–2026)
4.2 Global End-stage Renal Disease Therapeutics Forecasted Market Size by Type (2027–2032)
5 End-stage Renal Disease Therapeutics Breakdown Data by Application
5.1 Global End-stage Renal Disease Therapeutics Historic Market Size by Application (2021–2026)
5.2 Global End-stage Renal Disease Therapeutics Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America End-stage Renal Disease Therapeutics Market Size (2021–2032)
6.2 North America End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America End-stage Renal Disease Therapeutics Market Size by Country (2021–2026)
6.4 North America End-stage Renal Disease Therapeutics Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe End-stage Renal Disease Therapeutics Market Size (2021–2032)
7.2 Europe End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe End-stage Renal Disease Therapeutics Market Size by Country (2021–2026)
7.4 Europe End-stage Renal Disease Therapeutics Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific End-stage Renal Disease Therapeutics Market Size (2021–2032)
8.2 Asia-Pacific End-stage Renal Disease Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2021–2026)
8.4 Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America End-stage Renal Disease Therapeutics Market Size (2021–2032)
9.2 Latin America End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America End-stage Renal Disease Therapeutics Market Size by Country (2021–2026)
9.4 Latin America End-stage Renal Disease Therapeutics Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa End-stage Renal Disease Therapeutics Market Size (2021–2032)
10.2 Middle East & Africa End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2021–2026)
10.4 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Fresenius
11.1.1 Fresenius Company Details
11.1.2 Fresenius Business Overview
11.1.3 Fresenius End-stage Renal Disease Therapeutics Introduction
11.1.4 Fresenius Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.1.5 Fresenius Recent Development
11.2 Nikkiso
11.2.1 Nikkiso Company Details
11.2.2 Nikkiso Business Overview
11.2.3 Nikkiso End-stage Renal Disease Therapeutics Introduction
11.2.4 Nikkiso Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.2.5 Nikkiso Recent Development
11.3 B.Braun
11.3.1 B.Braun Company Details
11.3.2 B.Braun Business Overview
11.3.3 B.Braun End-stage Renal Disease Therapeutics Introduction
11.3.4 B.Braun Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.3.5 B.Braun Recent Development
11.4 Baxter
11.4.1 Baxter Company Details
11.4.2 Baxter Business Overview
11.4.3 Baxter End-stage Renal Disease Therapeutics Introduction
11.4.4 Baxter Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.4.5 Baxter Recent Development
11.5 Asahi Kasei
11.5.1 Asahi Kasei Company Details
11.5.2 Asahi Kasei Business Overview
11.5.3 Asahi Kasei End-stage Renal Disease Therapeutics Introduction
11.5.4 Asahi Kasei Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.5.5 Asahi Kasei Recent Development
11.6 Nipro
11.6.1 Nipro Company Details
11.6.2 Nipro Business Overview
11.6.3 Nipro End-stage Renal Disease Therapeutics Introduction
11.6.4 Nipro Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.6.5 Nipro Recent Development
11.7 Weigao
11.7.1 Weigao Company Details
11.7.2 Weigao Business Overview
11.7.3 Weigao End-stage Renal Disease Therapeutics Introduction
11.7.4 Weigao Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.7.5 Weigao Recent Development
11.8 Toray
11.8.1 Toray Company Details
11.8.2 Toray Business Overview
11.8.3 Toray End-stage Renal Disease Therapeutics Introduction
11.8.4 Toray Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.8.5 Toray Recent Development
11.9 Medtronic
11.9.1 Medtronic Company Details
11.9.2 Medtronic Business Overview
11.9.3 Medtronic End-stage Renal Disease Therapeutics Introduction
11.9.4 Medtronic Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.9.5 Medtronic Recent Development
11.10 JMS
11.10.1 JMS Company Details
11.10.2 JMS Business Overview
11.10.3 JMS End-stage Renal Disease Therapeutics Introduction
11.10.4 JMS Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.10.5 JMS Recent Development
11.11 SB-KAWASUMI
11.11.1 SB-KAWASUMI Company Details
11.11.2 SB-KAWASUMI Business Overview
11.11.3 SB-KAWASUMI End-stage Renal Disease Therapeutics Introduction
11.11.4 SB-KAWASUMI Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.11.5 SB-KAWASUMI Recent Development
11.12 Medica Group
11.12.1 Medica Group Company Details
11.12.2 Medica Group Business Overview
11.12.3 Medica Group End-stage Renal Disease Therapeutics Introduction
11.12.4 Medica Group Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.12.5 Medica Group Recent Development
11.13 Chongqing Shanwaishan
11.13.1 Chongqing Shanwaishan Company Details
11.13.2 Chongqing Shanwaishan Business Overview
11.13.3 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Introduction
11.13.4 Chongqing Shanwaishan Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.13.5 Chongqing Shanwaishan Recent Development
11.14 Amgen
11.14.1 Amgen Company Details
11.14.2 Amgen Business Overview
11.14.3 Amgen End-stage Renal Disease Therapeutics Introduction
11.14.4 Amgen Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.14.5 Amgen Recent Development
11.15 Deltanoid
11.15.1 Deltanoid Company Details
11.15.2 Deltanoid Business Overview
11.15.3 Deltanoid End-stage Renal Disease Therapeutics Introduction
11.15.4 Deltanoid Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.15.5 Deltanoid Recent Development
11.16 AbbVie
11.16.1 AbbVie Company Details
11.16.2 AbbVie Business Overview
11.16.3 AbbVie End-stage Renal Disease Therapeutics Introduction
11.16.4 AbbVie Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.16.5 AbbVie Recent Development
11.17 Sanofi
11.17.1 Sanofi Company Details
11.17.2 Sanofi Business Overview
11.17.3 Sanofi End-stage Renal Disease Therapeutics Introduction
11.17.4 Sanofi Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.17.5 Sanofi Recent Development
11.18 Ardelyx
11.18.1 Ardelyx Company Details
11.18.2 Ardelyx Business Overview
11.18.3 Ardelyx End-stage Renal Disease Therapeutics Introduction
11.18.4 Ardelyx Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.18.5 Ardelyx Recent Development
11.19 AstraZeneca
11.19.1 AstraZeneca Company Details
11.19.2 AstraZeneca Business Overview
11.19.3 AstraZeneca End-stage Renal Disease Therapeutics Introduction
11.19.4 AstraZeneca Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.19.5 AstraZeneca Recent Development
11.20 Kyowa Hakko Kirin
11.20.1 Kyowa Hakko Kirin Company Details
11.20.2 Kyowa Hakko Kirin Business Overview
11.20.3 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Introduction
11.20.4 Kyowa Hakko Kirin Revenue in End-stage Renal Disease Therapeutics Business (2021–2026)
11.20.5 Kyowa Hakko Kirin Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global End-stage Renal Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Drugs
Table 3. Key Players of Device
Table 4. Key Players of Other
Table 5. Global End-stage Renal Disease Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global End-stage Renal Disease Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global End-stage Renal Disease Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 8. Global End-stage Renal Disease Therapeutics Market Share by Region (2021–2026)
Table 9. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global End-stage Renal Disease Therapeutics Market Share by Region (2027–2032)
Table 11. End-stage Renal Disease Therapeutics Market Trends
Table 12. End-stage Renal Disease Therapeutics Market Drivers
Table 13. End-stage Renal Disease Therapeutics Market Challenges
Table 14. End-stage Renal Disease Therapeutics Market Restraints
Table 15. Global End-stage Renal Disease Therapeutics Revenue by Players (US$ Million), 2021–2026
Table 16. Global End-stage Renal Disease Therapeutics Market Share by Players (2021–2026)
Table 17. Global Top End-stage Renal Disease Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on End-stage Renal Disease Therapeutics Revenue, 2025
Table 18. Ranking of Global Top End-stage Renal Disease Therapeutics Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by End-stage Renal Disease Therapeutics Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of End-stage Renal Disease Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of End-stage Renal Disease Therapeutics, Products and Applications
Table 22. Global Key Players of End-stage Renal Disease Therapeutics, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global End-stage Renal Disease Therapeutics Market Size by Type (US$ Million), 2021–2026
Table 25. Global End-stage Renal Disease Therapeutics Revenue Market Share by Type (2021–2026)
Table 26. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global End-stage Renal Disease Therapeutics Revenue Market Share by Type (2027–2032)
Table 28. Global End-stage Renal Disease Therapeutics Market Size by Application (US$ Million), 2021–2026
Table 29. Global End-stage Renal Disease Therapeutics Revenue Market Share by Application (2021–2026)
Table 30. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global End-stage Renal Disease Therapeutics Revenue Market Share by Application (2027–2032)
Table 32. North America End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 34. North America End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 35. Europe End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 37. Europe End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific End-stage Renal Disease Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 47. Fresenius Company Details
Table 48. Fresenius Business Overview
Table 49. Fresenius End-stage Renal Disease Therapeutics Product
Table 50. Fresenius Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 51. Fresenius Recent Development
Table 52. Nikkiso Company Details
Table 53. Nikkiso Business Overview
Table 54. Nikkiso End-stage Renal Disease Therapeutics Product
Table 55. Nikkiso Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 56. Nikkiso Recent Development
Table 57. B.Braun Company Details
Table 58. B.Braun Business Overview
Table 59. B.Braun End-stage Renal Disease Therapeutics Product
Table 60. B.Braun Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 61. B.Braun Recent Development
Table 62. Baxter Company Details
Table 63. Baxter Business Overview
Table 64. Baxter End-stage Renal Disease Therapeutics Product
Table 65. Baxter Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 66. Baxter Recent Development
Table 67. Asahi Kasei Company Details
Table 68. Asahi Kasei Business Overview
Table 69. Asahi Kasei End-stage Renal Disease Therapeutics Product
Table 70. Asahi Kasei Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 71. Asahi Kasei Recent Development
Table 72. Nipro Company Details
Table 73. Nipro Business Overview
Table 74. Nipro End-stage Renal Disease Therapeutics Product
Table 75. Nipro Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 76. Nipro Recent Development
Table 77. Weigao Company Details
Table 78. Weigao Business Overview
Table 79. Weigao End-stage Renal Disease Therapeutics Product
Table 80. Weigao Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 81. Weigao Recent Development
Table 82. Toray Company Details
Table 83. Toray Business Overview
Table 84. Toray End-stage Renal Disease Therapeutics Product
Table 85. Toray Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 86. Toray Recent Development
Table 87. Medtronic Company Details
Table 88. Medtronic Business Overview
Table 89. Medtronic End-stage Renal Disease Therapeutics Product
Table 90. Medtronic Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 91. Medtronic Recent Development
Table 92. JMS Company Details
Table 93. JMS Business Overview
Table 94. JMS End-stage Renal Disease Therapeutics Product
Table 95. JMS Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 96. JMS Recent Development
Table 97. SB-KAWASUMI Company Details
Table 98. SB-KAWASUMI Business Overview
Table 99. SB-KAWASUMI End-stage Renal Disease Therapeutics Product
Table 100. SB-KAWASUMI Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 101. SB-KAWASUMI Recent Development
Table 102. Medica Group Company Details
Table 103. Medica Group Business Overview
Table 104. Medica Group End-stage Renal Disease Therapeutics Product
Table 105. Medica Group Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 106. Medica Group Recent Development
Table 107. Chongqing Shanwaishan Company Details
Table 108. Chongqing Shanwaishan Business Overview
Table 109. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product
Table 110. Chongqing Shanwaishan Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 111. Chongqing Shanwaishan Recent Development
Table 112. Amgen Company Details
Table 113. Amgen Business Overview
Table 114. Amgen End-stage Renal Disease Therapeutics Product
Table 115. Amgen Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 116. Amgen Recent Development
Table 117. Deltanoid Company Details
Table 118. Deltanoid Business Overview
Table 119. Deltanoid End-stage Renal Disease Therapeutics Product
Table 120. Deltanoid Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 121. Deltanoid Recent Development
Table 122. AbbVie Company Details
Table 123. AbbVie Business Overview
Table 124. AbbVie End-stage Renal Disease Therapeutics Product
Table 125. AbbVie Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 126. AbbVie Recent Development
Table 127. Sanofi Company Details
Table 128. Sanofi Business Overview
Table 129. Sanofi End-stage Renal Disease Therapeutics Product
Table 130. Sanofi Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 131. Sanofi Recent Development
Table 132. Ardelyx Company Details
Table 133. Ardelyx Business Overview
Table 134. Ardelyx End-stage Renal Disease Therapeutics Product
Table 135. Ardelyx Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 136. Ardelyx Recent Development
Table 137. AstraZeneca Company Details
Table 138. AstraZeneca Business Overview
Table 139. AstraZeneca End-stage Renal Disease Therapeutics Product
Table 140. AstraZeneca Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 141. AstraZeneca Recent Development
Table 142. Kyowa Hakko Kirin Company Details
Table 143. Kyowa Hakko Kirin Business Overview
Table 144. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product
Table 145. Kyowa Hakko Kirin Revenue in End-stage Renal Disease Therapeutics Business (US$ Million), 2021–2026
Table 146. Kyowa Hakko Kirin Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. Authors List of This Report
List of Figures
Figure 1. End-stage Renal Disease Therapeutics Picture
Figure 2. Global End-stage Renal Disease Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global End-stage Renal Disease Therapeutics Market Share by Type: 2025 vs 2032
Figure 4. Drugs Features
Figure 5. Device Features
Figure 6. Other Features
Figure 7. Global End-stage Renal Disease Therapeutics Market Size by Application (US$ Million), 2021–2032
Figure 8. Global End-stage Renal Disease Therapeutics Market Share by Application: 2025 vs 2032
Figure 9. Hospital Case Studies
Figure 10. Dialysis Center Case Studies
Figure 11. Other Case Studies
Figure 12. End-stage Renal Disease Therapeutics Report Years Considered
Figure 13. Global End-stage Renal Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global End-stage Renal Disease Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global End-stage Renal Disease Therapeutics Market Share by Region: 2025 vs 2032
Figure 16. Global End-stage Renal Disease Therapeutics Market Share by Players in 2025
Figure 17. Global End-stage Renal Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by End-stage Renal Disease Therapeutics Revenue in 2025
Figure 19. North America End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America End-stage Renal Disease Therapeutics Market Share by Country (2021–2032)
Figure 21. United States End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe End-stage Renal Disease Therapeutics Market Share by Country (2021–2032)
Figure 25. Germany End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific End-stage Renal Disease Therapeutics Market Share by Region (2021–2032)
Figure 33. China End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America End-stage Renal Disease Therapeutics Market Share by Country (2021–2032)
Figure 41. Mexico End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa End-stage Renal Disease Therapeutics Market Share by Country (2021–2032)
Figure 45. Israel End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE End-stage Renal Disease Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Fresenius Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 49. Nikkiso Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 50. B.Braun Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 51. Baxter Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 52. Asahi Kasei Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 53. Nipro Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 54. Weigao Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 55. Toray Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 56. Medtronic Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 57. JMS Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 58. SB-KAWASUMI Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 59. Medica Group Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 60. Chongqing Shanwaishan Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 61. Amgen Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 62. Deltanoid Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 63. AbbVie Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 64. Sanofi Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 65. Ardelyx Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 66. AstraZeneca Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 67. Kyowa Hakko Kirin Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2021–2026)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
